Denne indikation er i nogle medlemsstater begrænset til behandling efter hjerte - og nyretransplantation, i andre til behandling efter hjertetransplantation.
This indication was restricted to a treatment following cardiac and renal transplantation in some of these Member States and in some others restricted to a treatment following a cardiac transplant.